The cardioprotective potential of valsartan in myocardial ischaemia reperfusion injury

Central European Journal of Immunology

Volumn 40, Issue 2, 2015, Pages 159-166

  Hadi, Najah R ^a   Al Amran, Fhadil G ^a   Hussien, Yasmeem A ^a   Al Yasiri, Israa K ^a   Al Turfy, Mahamed ^a  

^a UNIVERSITY OF KUFA   (Iraq)

Author keywords

Ischaemia reperfusion injury; Valsartan

Indexed keywords

CASPASE 3; GLUTATHIONE; INTERLEUKIN 10; INTERLEUKIN 6; MALONALDEHYDE; PROTEIN BAX; PROTEIN BCL 2; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOPATHOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TISSUE PREPARATION;

EID: 84938560243     PISSN: 14263912     EISSN: 16444124     Source Type: Journal    
DOI: 10.5114/ceji.2015.52829     Document Type: Article

References (19)

1. Müller V, Losonczy G, Heemann U, et al. (2002): Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney Int 2002; 62: 1364-1371.
2. Saydam M, Takka S (2007): Bioavailability file: Valsartan. FABAD J Pharm Sci 2007; 32: 185-196.
3. Jung KH, Chu K, Lee ST, et al. (2007): Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 322: 1051-1058.
4. Navalkar S, Parthasarathy S, Santanam N, Khan BV (2001): Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 37: 440-444.
5. Varagic J, Frohlich ED, Susic D, et al. (2008): AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure. Am J Physiol Heart Circ Physiol 294: H853-858.
6. Jugdutt BI, Menon V (2008): Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by an-giotensin II type 1 receptor blockers during reperfused myo-cardial infarction in the rat. J Cardiovasc Pharmacol Ther 8: 217-226.
7. Wiedemann D, Schneeberger S, Friedl P, et al. (2010): The fibrin-derived peptide B beta (15-42) significantly attenuates ischemia-reperfusion injury in a cardiac transplant model. Transplantation 89: 824-829.
8. Zhang M, Xu YJ, Saini HK, et al. (2005): Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol 289: H832-839.
9. Zingarelli B, Salzman AL, Szabó C (1998): Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myo-cardial ischemia/reperfusion injury. Circ Res 83: 85-94.
10. Mathers CD, Loncar D (2006): Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
11. Wu L, Iwai M, Nakagami H, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angio-tensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001; 104: 2716-2721.
12. Wu B, Lin R, Dai R, et al. (2013): Valsartan attenuates oxida-tive stress and NF-kappaB activation and reduces myocardial apoptosis after ischemia and reperfusion. Eur J Pharmacol 705: 140-147.
13. Ning XF, Zhang WZ, Liu S, et al. (2008): Cardioprotective effect of valsartan on cardiac ischemic-reperfusion injury. Department of cardiology, the affiliated hospital of Qingdao University Medical College, Qingdao 266003, China.
14. Jung KH, Chu K, Lee ST, et al. (2007): Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther 322: 1051-1058.
15. Bozcali E, Dedeoglu DB, Karpuz V, et al. (2012): Cardiopro-tective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardio-toxicity. Acta Cardiol 67: 87-96.
16. Goette A, Bukowska A, Dobrev D, et al. (2009): Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J 30: 1411-1420.
17. Fogari R, Mugellini A, Zoppi A, et al. (2012): Effect of tel-misartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther 17: 34-43.
18. Tawfik MK (2012): Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats. Eur Rev Med Pharmacol Sci 16: 600-609.
19. Yang J, Jiang H, Yang J, et al. (2009): Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway. Mol Cell Biochem 330: 39-46.